Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.

Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days.
Patients evaluate the Functional Grade（FG） and Arm Grade（AG） et al.
As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.